Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting

References

• Wolff AC, Hammond MEH, Hicks DG., et al. recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256. doi:10.5858/arpa.2013-0953-SA
   PubMed Web of Science ®Google Scholar
• NCCN. Breast Cancer Version 1.2019; 2019.
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu Oncogene. science. 1987;235(4785):177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244–248. doi:10.1016/S1470-2045(13)70017-2
   PubMed Web of Science ®Google Scholar
• Gennari A, André F, Barrios C, et al. ESMO Clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. Ann Oncol. 2021;32:1475–1495.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–2977. doi:10.1002/cncr.11436
   PubMed Web of Science ®Google Scholar
• Altaha R, Crowell E, Ducatman B, Higa G, Abraham J. Risk of brain metastases in HER2/neu-positive breast cancer. J clin oncol. 2004;22(14_suppl):682. doi:10.1200/jco.2004.22.90140.682
   Google Scholar
• Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer. 2004;91(4):639–643. doi:10.1038/sj.bjc.6601970
   PubMed Web of Science ®Google Scholar
• Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Translat Med. 2018;6(9):163. doi:10.21037/atm.2018.04.35
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–3277. doi:10.1200/JCO.2009.25.9820
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18(11):2349–2351. doi:10.1200/JCO.2000.18.11.2349
   PubMed Web of Science ®Google Scholar
• Stemmler J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol. 2006;24(18_suppl):1525. doi:10.1200/jco.2006.24.18_suppl.1525
   Web of Science ®Google Scholar
• Zimmer AS, Van Swearingen AE, Anders CK. HER2‐positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep. 2022;5:e1274.
   Google Scholar
• Galanti D, Inno A, La Vecchia M, et al. Current treatment options for HER2-positive breast cancer patients with brain metastases. Crit Rev Oncol Hematol. 2021;161:103329. doi:10.1016/j.critrevonc.2021.103329
   PubMed Web of Science ®Google Scholar
• Anders CK. Management of brain metastases in breast cancer. Clin Adv Hematol Oncol. 2016;14:686–688.
   PubMedGoogle Scholar
• Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6):1648–1655. doi:10.1158/1078-0432.CCR-06-2478
   PubMed Web of Science ®Google Scholar
• Klos KJ, O’Neill BP. Brain metastases. Neurologist. 2004;10(1):31–46. doi:10.1097/01.nrl.0000106922.83090.71
   PubMed Web of Science ®Google Scholar
• Niikura N, Hayashi N, Masuda N, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014;147(1):103–112. doi:10.1007/s10549-014-3090-8
   PubMed Web of Science ®Google Scholar
• Aversa C, Rossi V, Geuna E, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast. 2014;23(5):623–628. doi:10.1016/j.breast.2014.06.009
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neuro-oncol. 2013;112(3):467–472. doi:10.1007/s11060-013-1083-9
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, Phase 3 trial. Lancet. 2022;2:5
   Google Scholar
• Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321–329. doi:10.1016/j.annonc.2021.12.005
   PubMed Web of Science ®Google Scholar
• Rosen B, Waitzberg R, Merkur S. Health systems in transition. Israel. 2015;1:3
   Google Scholar
• Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol. 2011;152(3):345–349. doi:10.1016/j.ijcard.2010.08.002
   PubMed Web of Science ®Google Scholar
• Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur j epidemiol. 2003;18(12):1143–1146. doi:10.1023/B:EJEP.0000006635.36802.c8
   PubMed Web of Science ®Google Scholar
• Goldshtein I, Chandler J, Shalev V, et al. Osteoporosis in the community: findings from a novel computerized registry in a large Health Organization in Israel. J Aging Res Clin Pract. 2015;3:4.
   Google Scholar
• Israel Central Bureau of Statistics. Characterization and Classification of Geographic Units by the Soci-Economic Level of the Population 2008. Publication No. 1530. Jerusalem, Israel: Israel Central Bureau of Statistics; 2013.
   Google Scholar
• Machado M, de Moura CS, Chan K, et al. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. Sci Rep. 2020;10(1):14607. doi:10.1038/s41598-020-71788-z
   PubMed Web of Science ®Google Scholar
• Pan X, Lin M, Yin Y, Hou P, Baumann P, Jahanzeb M. Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States. Ann Oncol. 2019;30:ii52–ii3.
   Web of Science ®Google Scholar
• Moser SS, Apter L, Arunachalam A, et al. Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel. Immunotherapy. 2021;13(10):851–861. doi:10.2217/imt-2020-0347
   PubMed Web of Science ®Google Scholar
• Amiri-Kordestani L, Wilkerson J, Balasubramaniam S, Bates SE, Fojo AT. Difference between duration of treatment (DOT) and progression-free survival (PFS) as a marker of unbalanced censoring. J clin oncol. 2012;30(15_suppl):2548. doi:10.1200/jco.2012.30.15_suppl.2548
   Web of Science ®Google Scholar
• FOCR. Establishing a framework to evaluate real-world endpoints; 2018.
   Google Scholar
• Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy. 2019;11(10):889–901. doi:10.2217/imt-2019-0061
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119. doi:10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Ramakrishna N, Anders CK, Lin NU, et al. Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: ASCO guideline update. J clin oncol. 2022;40(23):2636–2655. doi:10.1200/JCO.22.00520
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742. doi:10.1016/S1470-2045(17)30312-1
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–4843. doi:10.1158/1078-0432.CCR-10-2962
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa1914609
   PubMed Web of Science ®Google Scholar
• Lin NU, Borges V, Anders C, et al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J clin oncol. 2020;38(23):2610–2619. doi:10.1200/JCO.20.00775
   PubMed Web of Science ®Google Scholar
• Polivka J, Kralickova M, Polivka J, Kaiser C, Kuhn W, Golubnitschaja O. Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J. 2017;8(2):119–127. doi:10.1007/s13167-017-0087-5
   PubMed Web of Science ®Google Scholar
• Kapinova A, Mazurakova A, Halasova E, et al. Underexplored reciprocity between genome-wide methylation status and long non-coding RNA expression reflected in breast cancer research: potential impacts for the disease management in the framework of 3P medicine. EPMA J. 2023;14(2):249–273. doi:10.1007/s13167-023-00323-7
   PubMed Web of Science ®Google Scholar
• Huang X, Chen Z, Xiang X, et al. Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine. EPMA J. 2022;13(4):671–697. doi:10.1007/s13167-022-00305-1
   PubMed Web of Science ®Google Scholar
• Crigna AT, Samec M, Koklesova L, et al. Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? EPMA J. 2020;11(4):603–627. doi:10.1007/s13167-020-00226-x
   PubMed Web of Science ®Google Scholar
• Mazurakova A, Koklesova L, Samec M, et al. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. EPMA J. 2022;13(2):315–334. doi:10.1007/s13167-022-00277-2
   PubMed Web of Science ®Google Scholar
• Figura NB, Rizk VT, Armaghani AJ, et al. Breast leptomeningeal disease: a review of current practices and updates on management. Breast Cancer Res Treat. 2019;177(2):277–294. doi:10.1007/s10549-019-05317-6
   PubMed Web of Science ®Google Scholar
• Pérez-García JM, Batista MV, Cortez-Castedo P, et al. Abstract PD7-02: trastuzumab deruxtecan in patients with unstable central nervous system involvement from HER2-Low Advanced Breast Cancer: the DEBBRAH trial. Cancer Res. 2023;83(5_Supplement):PD7. doi:10.1158/1538-7445.SABCS22-PD7-02
   Web of Science ®Google Scholar